Andy Slavitt

Health Datapalooza: New Vistas

By Susannah Fox – Every spring, our team in the HHS IDEA Lab gears up for our biggest event of the year: the Health Datapalooza. It’s an annual celebration of the power of data that was started by my predecessor, Todd Park, in 2010. This year, we were honored to hear from an extraordinary lineup of leaders from private industry, academia and the federal government, including Vice President Biden.

Read More

Moving Toward Improved Care Through Information

By Karen B. DeSalvo MD & Andy Slavitt – Seven years ago, Congress passed a law to spur the country to digitize the health care experience for Americans and connect doctor’s practices and hospitals, thereby modernizing patient care through the Electronic Health Records (EHRs) Incentive Programs, also known as “Meaningful Use.”


Reflections on CMS and the Successful Implementation of ICD-10

By Andy Slavitt – It was early 2015 and we had just gotten through a second successful season with HealthCare.gov, the turnaround that originally brought me into government, when the articles and letters started flying on our next big implementation – one that would affect nearly every physician and hospital in the country. And, anxiety levels were high.




EHR Incentive Programs

By Andy Slavitt & Karen DeSalvo – As we mentioned in a speech previously, the Administration is working on an important transition for the Electronic Health Record (EHR) Incentive Program. We have been working side by side with physician organizations and have listened to the needs and concerns of many about how we can make improvements that will allow technology to best support clinicians and their patients.




Medicare Drug Spending Dashboard

By Andy Slavitt & Niall Brennan – Just over a month ago, HHS convened a forum that brought together consumers, providers, employers, manufacturers, health insurance companies, representatives from state and federal government, and other stakeholders to discuss ideas on how our country can meet the dual imperatives of encouraging drug development and innovation, while ensuring access and affordability.